New Coverage: Veru Inc. (NASDAQ: VERU) Just Hit the Top of Our Tuesday Watchlist

*Sponsored One Little-Known BioPharma Just Jumped to the Top of Our Tuesday Watchlist! Krypton Street Announces Coverage On Veru Inc. (NASDAQ: VERU). Here’s Why… Advancing In A Sector Projected To Exceed $470B With 900%+  Forecasted Growth. Phase 2b Data Shows Encouraging Results When Combined With  Metabolic Therapy. Power Player Worth $2B+, Dr. Frost Holds 5M+ Shares And Brings A  Long Track Record Of Strategic Healthcare Moves. Backed By Over $26M In Ca-sh And Equivalents To Support  Ongoing Development. Analyst Target Suggests Over 716% Upside Potential. Pull Up Veru Inc. (NASDAQ: VERU) Before Tomorrow Morning… March 31, 2025 Dear Reader, It’s been a day of early movers—our clean-tech profile hit $0.86 before the bell, marking an approximate 21% move overnight. Now, as we scan what’s setting up next, one name has just landed at the top of our radar. This is the kind of setup we look for. Not hype. No noise. But a developing story backed by real science, clear momentum, and a set of data points that demand a closer look. Quietly, this company is targeting one of the most aggressively expanding segments in healthcare—one that could exceed $470B, with projections pointing to 900%+ growth within the next 7-8 years. And while the market remains focused on the usual suspects, Veru Inc. (NASDAQ: VERU) is building something most haven’t accounted for yet. Here’s What Caught Our Eye First: Analyst Targets Are Rising—Fast  Despite minimal media exposure, four institutional firms have already issued coverage on Veru—and their targets suggest this name may be overlooked: Oppenheimer: $4 target (716% potential upside.) Raymond James: $3 target (512% potential upside.) H.C. Wainwright & Co.: $2.50 target (410% potential upside.) B. Riley Financial: $2 target (308% potential upside.) That level of alignment—especially across four independent firms—doesn’t happen often unless something has shifted. And it has. A Quiet Power Player Steps In While analyst coverage gives us one signal, ownership is another. And few names carry the kind of weight in healthcare that Dr. Phillip Frost does. Known for helping build and scale Key Pharmaceuticals and Ivax, Dr. Frost has secured over 5M shares of Veru Inc. (NASDAQ: VERU)—an unusual move for someone who could allocate capital anywhere. His resume includes: A sale of Key Pharmaceuticals for $836M Leading Ivax before its $7.6B acquisition by Teva And with a current net worth exceeding $2B, his track record of backing early-stage names that go the distance speaks for itself. This is not casual interest.  It’s conviction. Why Veru Inc. (NASDAQ: VERU)’s Trial Results Could Signal a Turning Point At the center of the story is Enobosarm—a compound focused on reducing fat while preserving muscle. That may sound simple. It’s not. Here’s why this distinction matters: Most wei-ght loss therapies lead to loss of lean muscle and bone density That muscle loss poses risks—especially for aging patients or those managing chronic illness Veru’s approach shifts the focus from weight on the scale to body composition—a far more meaningful clinical outcome In its Phase 2b QUALITY trial, Enobosarm was combined with a widely used metabolic therapy and delivered: Reduction in fat mass Preservation of lean muscle Improved body composition across key endpoint With a pivotal Phase 3 trial now in planning and FDA oversight in place, Veru is entering a stage that many peers never reach. Here’s  5 Reasons Why Veru Inc. (NASDAQ: VERU) Just Jump To The Top Of Our Tuesday Watchlist—Get Ready Now… 1. Analyst Coverage: Four institutional firms have set targets that suggest triple-digital upside potential—including 410%, 512%, and 716%. 2. Sector Forecast to Multiply 9X: The company is advancing in a category projected to exceed $470B, with sector-wide growth forecasts above 900%. 3. Strong Phase 2b Data: Enobosarm has already shown encouraging results alongside standard metabolic therapy. 4. Power Player Worth $2B+ Is In: Dr. Frost’s stake (5M+ shares) isn’t just capital—it’s a long-term signal. 5. Well-Funded: Over $26M in ca-sh and equivalents allows Veru Inc. (NASDAQ: VERU) to execute without delay. Keep An Eye On Veru Inc. (NASDAQ: VERU) Tomorrow Morning… Veru Inc. (NASDAQ: VERU) may not stay under the radar much longer. The combination of clinical momentum, strategic backing, analyst attention, and sector tailwinds is rare to find in a name priced under $1. We will have (VERU) at the top of our screens early tomorrow—and this is your chance to be one of the first to do the same. Take a look at (VERU) before tomorrow morning. And keep an eye out for my morning update. Rest up—we’re gonna be ready bright and early. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/17/2025 and ending on 04/01/2025 to publicly disseminate information about (VERU:US) via digital communications. Under this agreement, Media 1717 LLC has been paid ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (VERU:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/veru/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice